NCT04874129

Phase 1 to Evaluate the Safety and Pharmacokinetic Characteristics of Fixed-dose Combination of YYC506

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Yooyoung Pharmaceutical Co., Ltd. · Industry
• Sex: Male
• Age: 19 Years
• Healthy volunteers: Accepted

Summary

To evaluate the safety and pharmacokinetics characteristics between YYC506 and concomitant administration of YYC506-T and YYC506-A

Detailed description

Phase 1 to evaluate the safety and pharmacokinetics characteristics between YYC506 and concomitant administration of YYC506-T and YYC506-A. Which is designed as ramdomized, oral, single dose, two-way crossover.

Conditions

• Dyslipidemias

Interventions

Type	Name	Description
DRUG	YYC506-T and YYC506-A (phase 1)	Comparator
DRUG	YYC506 (phase 1)	Test
DRUG	YYC506-T and YYC506-A (phase 2)	Comparator
DRUG	YYC506 (phase 2)	Test

Timeline

• Start date: 2021-01-07
• Primary completion: 2021-05-31
• Completion: 2021-07-31
• First posted: 2021-05-05
• Last updated: 2021-05-05

Locations

1 site across 1 country: South Korea